KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Ken Kato, Manish A Shah, Peter Enzinger, Jaafar Bennouna, Lin Shen, Antoine Adenis, Jong-Mu Sun, Byoung Chul Cho, Mustafa Özgüroğlu, Takashi Kojima, Vladimir Kostorov, Cinta Hierro, Ying Zhu, Lee Anne McLean, Sukrut Shah, Toshihiko Doi, Ken Kato, Manish A Shah, Peter Enzinger, Jaafar Bennouna, Lin Shen, Antoine Adenis, Jong-Mu Sun, Byoung Chul Cho, Mustafa Özgüroğlu, Takashi Kojima, Vladimir Kostorov, Cinta Hierro, Ying Zhu, Lee Anne McLean, Sukrut Shah, Toshihiko Doi
Abstract
Background: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer.
Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov : NCT03189719.
Keywords: PD-1; PD-L1; chemotherapy; esophageal cancer; esophagogastric junction cancer; gastrointestinal/esophageal; immunotherapy; pembrolizumab; squamous cell carcinoma of the esophagus.
Source: PubMed